COVID-19 vaccination provides a foundation of protection that’s enhanced by breakthrough infection; ‘the key is to get vaccinated.’
Breakthrough infections greatly enhance immune response to variants of the virus that causes COVID-19, according to a newly published study from Oregon Health & Science University.
The laboratory results, published online ahead of print in the Journal of the American Medical Association (JAMA), reveals that a breakthrough infection generates a robust immune response against the delta variant. Authors say the findings suggest the immune response is likely to be highly effective against other variants as the SARS-CoV-2 virus continues to mutate.
The study is the first to use live SARS-CoV-2 variants to measure cross-neutralization of blood serum from breakthrough cases.
“You can’t get a better immune response than this,” said senior author Fikadu Tafesse, Ph.D., assistant professor of molecular microbiology and immunology in the OHSU School of Medicine. “These vaccines are very effective against severe disease. Our study suggests that individuals who are vaccinated and then exposed to a breakthrough infection have super immunity.”
The study found that antibodies measured in blood samples of breakthrough cases were both more abundant and much more effective – as much as 1,000% more effective – than antibodies generated two weeks following the second dose of the Pfizer vaccine.
The study suggests each exposure following vaccination actually serves to strengthen immune response to subsequent exposures even to new variants of the virus.
“I think this speaks to an eventual end game,” said co-author Marcel Curlin, M.D., associate professor of medicine (infectious diseases) in the OHSU School of Medicine who also serves as medical director of OHSU Occupational Health. “It doesn’t mean we’re at the end of the pandemic, but it points to where we’re likely to land: Once you’re vaccinated and then exposed to the virus, you’re probably going to be reasonably well-protected from future variants.
“Our study implies that the long-term outcome is going to be a tapering-off of the severity of the worldwide epidemic.”
Vaccine immunity is currently undergoing a real-world test against the new omicron variant.
“We have not examined the omicron variant specifically, but based on the results of this study we would anticipate that breakthrough infections from the omicron variant will generate a similarly strong immune response among vaccinated people,” Tafesse said.
The study compared blood samples collected from a total of 52 people, all employees of OHSU who were vaccinated with the Pfizer vaccine and subsequently enrolled in the study.
A total of 26 people were identified through OHSU Occupational Health testing as having mild breakthrough infections following vaccination. Among the sequence-confirmed breakthrough cases, 10 involved the highly contagious delta variant, nine were non-delta and seven were unknown variants.
Working in a Biosafety Level 3 lab, researchers then measured immune response to live virus exposed to blood sampled from people with breakthrough cases and compared it with the immune response to the control group. They found the breakthrough cases generated more antibodies at baseline, and they found that those antibodies were substantially better at neutralizing the live virus.
With as many as one in five eligible Oregonians still vulnerable to infection – and vaccination rates even lower elsewhere in the country and around the world – the new study underscores the fact that vaccination remains the key to ending the pandemic.
“The key is to get vaccinated,” Curlin said. “You’ve got to have a foundation of protection.”
Reference: “Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection” by Timothy A. Bates, BSc; Savannah K. McBride, BSc; Bradie Winders, CNA; Devin Schoen, BSc; Lydie Trautmann, EngD, PhD; Marcel E. Curlin, MD and Fikadu G. Tafesse, PhD, 16 December 2021, Journal of the American Medical Association (JAMA).
The study was funded by an unrestricted grant from the M.J. Murdock Charitable Trust; an unrestricted grant from the OHSU Foundation; the National Institutes of Health training grant T32HL083808; and OHSU Innovative IDEA grant 1018784.